ArticleJournal of medical virology2003
Synergistic antiviral effect of a combination of mouse interferon-alpha and interferon-gamma on mouse hepatitis virus.
Article in Journal of medical virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Tackling SARS-CoV-2: proposed targets and repurposed drugs.Future medicinal chemistry · 2020Review
- Interferon gamma modulation of disease manifestation and the local antibody response to alphavirus encephalomyelitis.The Journal of general virology · 2016Article
- Coronavirus virulence genes with main focus on SARS-CoV envelope gene.Virus research · 2014Review
- Elucidating the host-pathogen interaction between human colorectal cells and invading Enterovirus 71 using transcriptomics profiling.FEBS open bio · 2014Article
- Article
- Murine coronavirus delays expression of a subset of interferon-stimulated genes.Journal of virology · 2010Article
- Murine Coronavirus Cell Type Dependent Interaction with the Type I Interferon Response.Viruses · 2009Article
- Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication.The Journal of biological chemistry · 2008Article
- Tumor necrosis factor and interferon: cytokines in harmony.Current opinion in microbiology · 2008Review
- Interferon and cytokine responses to SARS-coronavirus infection.Cytokine & growth factor reviews · 2008Review
- Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells.Journal of virology · 2008Article
- Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons.Journal of virology · 2007Article
- Development of antiviral therapy for severe acute respiratory syndrome.Antiviral research · 2005Review
- Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3.Journal of virology · 2005Article
- Role of interferons in the treatment of severe acute respiratory syndrome.Expert opinion on biological therapy · 2004Review
- Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth.Journal of virology · 2004Article
- Current concepts in SARS treatment.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2004Review
- Hyper-activated IRF-1 and STAT1 contribute to enhanced interferon stimulated gene (ISG) expression by interferon alpha and gamma co-treatment in human hepatoma cells.Biochimica et biophysica actaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although interferon (IFN)-alpha and IFN-gamma have been reported to exhibit a synergistic antiviral effect through the different signaling pathways in vitro, their therapeutic efficacy is not well defined in vivo. The current study was carried out to investigate the combined antiviral effect in a model of mouse hepatitis virus Type 2 (MHV-2) infection, in which fulminant hepatitis is developed. MHV-2 was injected intraperitoneally into 4-week-old ICR mice, IFN or the vehicle was administered intramuscularly for 5 days, and the antiviral effect was evaluated based on survival periods, liver histology, serum alanine transaminase (ALT) levels, and MHV-2 virus titers in the liver tissues. The animals in the group treated with a combination of IFN-alpha and IFN-gamma survived for longer periods than the groups treated with IFN-alpha alone and IFN-gamma alone (IFN-alpha 10(3) (IU/mouse)/-gamma 10(3) vs. IFN-alpha 10(3), P < 0.005; IFN-alpha 10(3)/-gamma 10(3) vs. IFN-gamma 10(3), P < 0.001). This is consistent with the lower levels of hepatocellular necrosis and serum ALT and the decreased titers of MHV-2 virus in the liver tissues (48 hr, P < 0.001; 72 hr, P < 0.001). These findings indicate that a combination of IFN-alpha and IFN-gamma exhibits a synergistic antiviral effect on MHV-2 infection. The biology of MHV-2 is quite different from that of human hepatitis viruses; however, these results suggest the beneficial combined therapy of IFN-alpha and IFN-gamma for the treatment of human viral hepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.